Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Get essential year-end tax filing guidance for DRIP ETFs, including records to gather and strategies to reduce liabilities.
24,400 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Standard Chartered trims its XRP outlook to $2.80, a 65% drop that marks the sharpest forecast revision among its cry...
A neighbor’s request to borrow a snowblower tests whether sharing costly equipment makes financial sense. The article...
The FDA has issued a recall of Elite Treats Chicken Chips for Dogs due to potential salmonella contamination. No illn...
FedEx says it will return tariff refunds to customers who paid them after a Supreme Court ruling curbed IEEPA tariffs...
A U.S. strike on Iran triggered a rapid reevaluation of crypto mining and Bitcoin hashrate resilience, with analysts ...
Circle stock jumped february as investors weighed an earnings beat against a choppy crypto backdrop. This article unp...
The Federal Reserve approved Kraken for a master account, triggering a wave of concern from bank groups about regulat...
CrowdStrike has shown momentum, but the stock carries risk. Here’s why I’m skeptical and how investors can approach c...
A nationwide rise in foreclosure starts 19% signals mounting pressure in select counties. This guide breaks down wher...
Analysts say ethereum price predictions analyst signals point to a potential rebound as ETH tests a key support, with...
As Alphabet shifts its advertising footprint and data strategy, Disney investors just really need to understand the p...